Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Senzime ABOSTO:SEZI -2.70%71 Market Cap is kr566.0 Mil as of Jul. 27, 2026. GuruFocus rates OSTO:SEZI with a GF Score™ of 71/100 and a GF Value™ of kr9.06 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 863 Medical Devices & Instruments companies, Senzime AB ranks worse than 58.86% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Senzime AB's share price for the quarter that ended in Jun. 2026 was kr4.33. Senzime AB's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 157.2 Mil. Therefore, Senzime AB's market cap for the quarter that ended in Jun. 2026 was kr680.7 Mil.
Senzime AB's quarterly market cap
declined
from Dec. 2025 (kr849.0 Mil) to Mar. 2026 (kr659.5 Mil) but then
increased
from Mar. 2026 (kr659.5 Mil) to Jun. 2026 (kr680.7 Mil).
Senzime AB's annual market cap
declined
from Dec. 2023 (kr889.4 Mil) to Dec. 2024 (kr732.5 Mil) but then
increased
from Dec. 2024 (kr732.5 Mil) to Dec. 2025 (kr849.0 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Senzime AB's Enterprise Value for Today is kr550.2 Mil.
Senzime AB (OSTO:SEZI) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Senzime AB Market Cap Related Terms
Senzime AB Market Cap Historical Data
* Premium members only.
The historical data trend for Senzime AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Senzime AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senzime AB Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Senzime AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Senzime AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Senzime AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senzime AB (OSTO:SEZI) has a Market Cap of kr566.0 Mil as of Jul. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Senzime AB and its competitors. According to the industry distribution chart, Senzime AB ranks #508 out of 863 companies in the Medical Devices & Instruments industry, placing it in the top 58.9%.
Is Senzime AB's Market Cap too high?
Senzime AB's current Market Cap is kr566.0 Mil. Based on the distribution chart, Senzime AB ranks #508 out of 863 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Senzime AB has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Senzime AB's Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Senzime AB ranks #508 out of 863 companies for Market Cap. This places Senzime AB in the lower half of its industry. The industry median Market Cap is 114.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 114.85, based on 863 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Senzime AB and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 114.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senzime AB's current Market Cap is kr566.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senzime AB stock overvalued right now?
Based on GuruFocus' analysis, Senzime AB (OSTO:SEZI) is currently considered Possible Value Trap. The stock's GF Value™ is kr9.06, compared to a current price of kr3.60 — trading 60.3% below its estimated fair value. The current Market Cap is kr566.0 Mil. Senzime AB's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Senzime AB (OSTO:SEZI), the current Market Cap is kr566.0 Mil as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Senzime AB (OSTO:SEZI) Overvalued in 2026?
Based on GuruFocus' analysis, Senzime AB stock appears to be undervalued.
The current stock price of kr3.60 is trading 60.3% below its estimated GF Value™ of kr9.06.
GuruFocus considers Senzime AB to be Possible Value Trap.
Key valuation signals for OSTO:SEZI:
Market Cap: kr566.0 Mil
GF Value™: kr9.06 vs. price of kr3.60 (60.3% below fair value)
No single metric tells the full story. See the OSTO:SEZI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Senzime AB is a medical device company developing precision-based patient monitoring solutions for patients undergoing anesthesia. The company develops and markets precision-based monitoring systems for monitoring neuromuscular function and respiration during and after surgery, as well as for intensive care. Its product portfolio includes Next-generation TetraGraph, TetraGraph connectivity, TetraGraph for pediatric, Classic TetraGraph, and ExSpiron. The TetraGraph system is used in thousands of operating rooms internationally in university hospitals, public, private, military, and veterans hospitals. Senzime has direct sales resources in the USA and Germany and collaborates with distributors and licensees in its other main markets.
71GF Score
Get the complete analysis for OSTO:SEZI
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SEZI has been successfully added to your 
